Status:
TERMINATED
Tamoxifen Resistance in Women With Stage I, Stage II, Stage IIIA, or Stage IIIB Breast Cancer
Lead Sponsor:
Wake Forest University Health Sciences
Collaborating Sponsors:
National Cancer Institute (NCI)
Conditions:
Breast Cancer
Eligibility:
FEMALE
18-120 years
Brief Summary
RATIONALE: Studying samples of blood from patients with breast cancer in the laboratory may help doctors identify and learn more about biomarkers related to tamoxifen resistance. PURPOSE: This labora...
Detailed Description
OBJECTIVES: * Identify women who are resistant to tamoxifen citrate and other drugs for the treatment of breast cancer by testing their plasma for the presence of proteins (e.g., macrophage migration...
Eligibility Criteria
Inclusion
- Histologically confirmed invasive breast cancer
- Initial pathologic stage I-IIIB disease
- No stage IV disease
- Meets the following criteria for breast cancer therapy:
- Received prior primary local therapy for breast cancer
- Scheduled to begin tamoxifen citrate as adjuvant therapy for breast cancer within 3 weeks
- Hormone receptor status:
- Estrogen-receptor positive tumor
- Female
- Pre- or post-menopausal
- Must be able to donate 20 mL of blood
Exclusion
- Severe anemia, defined as hemoglobin \< 11 g/dL
- Psychiatric history that would preclude obtaining informed consent
Key Trial Info
Start Date :
May 1 2007
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 1 2012
Estimated Enrollment :
2 Patients enrolled
Trial Details
Trial ID
NCT00899197
Start Date
May 1 2007
End Date
June 1 2012
Last Update
August 1 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Wake Forest University Comprehensive Cancer Center
Winston-Salem, North Carolina, United States, 27157-1096